Progenics Pharmaceuticals (PGNX) Form 3 PROGENICS PHARMACEUTICALS / Vivien Wong ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Wong Vivien

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2015

3. Issuer Name and Ticker or Trading Symbol
PROGENICS PHARMACEUTICALS INC [ PGNX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Executive Vice President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,121	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	(1)	03/03/2024	Common Stock	127,800	4.7	D
Non-Qualified Stock Option (right to buy)	(2)	11/01/2020	Common Stock	25,000	4.83	D
Non-Qualified Stock Option (right to buy)	(2)	04/04/2023	Common Stock	48,000	5.03	D
Non-Qualified Stock Option (right to buy)	(2)	07/01/2019	Common Stock	3,375	5.33	D
Non-Qualified Stock Option (right to buy)	(2)	07/01/2020	Common Stock	6,000	5.35	D
Non-Qualified Stock Option (right to buy)	(2)	03/02/2025	Common Stock	66,000	6.65	D
Non-Qualified Stock Option (right to buy)	(2)	07/01/2021	Common Stock	60,000	7.4	D
Non-Qualified Stock Option (right to buy)	(2)	03/01/2022	Common Stock	40,000	9.81	D
Non-Qualified Stock Option (right to buy)	(2)	07/01/2018	Common Stock	2,589	16.05	D
Non-Qualified Stock Option (right to buy)	(3)	11/01/2017	Common Stock	6,000	22.67	D

Explanation of Responses:

1. Amount consists of 2 separate grants. 75,000 stock options become exercisable in four equal annual installments and 52,800 become exercisable in three equal annual installments both commencing one year from grant date.

2. The stock options become exercisable in three equal annual installments, commencing one year from the grant date.

3. The stock options become exercisable in five equal installments, commencing one year from the grant date.

	/s/ Vivien Wong	04/01/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.